Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
A-1899 is an inhibitor of the two-pore domain potassium channel 3.1 (K2P3.1/TASK1; IC50 = 0.035 µM in Xenopus oocytes expressing the human channel).1 It is selective for K2P3.1/TASK1 over K2P5.1/TASK2, K2P9.1/TASK3, and K2P17.1/TASK4 (IC50s = 12, 0.318, and 8.1 µM, respectively) and a panel of 16 additional potassium channels at 0.1 µM. A-1899 (3 mg/kg) selectively increases the effective refractory period (ERP) in the left atrium over the right atrium and does not affect ventricular repolarization in anesthetized pigs.2 It stimulates breathing and induces respiratory alkalosis in spontaneously breathing anesthetized rats when administered at a dose of 25 mg/kg.3
WARNING This product is not for human or veterinary use.
1. A specific two-
2. Electrophysiological and antiarrhythmic effects of the novel IKur channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the IKr blockers dofetilide, azimilide, d,l-
3. TASK-